Recent news that the US Food and Drug Administration (FDA) will ask cell and gene therapy (CGT) developers to provide more consistent evidence with their submissions has resulted in drug makers delaying development plans — and working on new ways to address the agency’s concerns
Paradigm4 announces the general availability of flexFS, a hyperscale file system designed for AI/ML and large file data workloads, providing unparalleled throughput at 50% lower cost
Over the past 5 decades or so, the growing understanding that RNA can influence protein function through routes other than direct translation has opened the prospect of discovering small molecules for tackling diseases in novel ways.
Single-cell technologies have positioned themselves at the forefront of biomedical research. These platforms allow researchers to bypass the uncertainties of bulk data and instead interrogate biological systems at a level of detail that was previously unreachable. But the value of these systems risks being impaired by bottlenecks in data analysis
